{"component": "definition", "props": {"groups": [{"size": 16, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "good-laboratory-practices", "type": "definition", "offset": [94, 119]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [120, 139]}, {"key": "duration-of", "type": "definition", "offset": [175, 186]}, {"key": "regulatory-submission", "type": "clause", "offset": [289, 310]}, {"key": "human-subjects", "type": "clause", "offset": [336, 350]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [392, 418]}, {"key": "toxicology-studies", "type": "definition", "offset": [432, 450]}], "samples": [{"hash": "kFCOvBekbUe", "uri": "/contracts/kFCOvBekbUe#glp-tox-study", "label": "License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 35.3682403564, "published": true}, {"hash": "eZw8VhlZ7Ch", "uri": "/contracts/eZw8VhlZ7Ch#glp-tox-study", "label": "License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.5776863098, "published": true}, {"hash": "1F7NiN3Blxq", "uri": "/contracts/1F7NiN3Blxq#glp-tox-study", "label": "License and Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.353181839, "published": true}], "snippet": "means, with respect to a Compound, a study conducted in a species using applicable regulatory good laboratory practices for the purposes of assessing the onset, severity, and duration of toxic effects and their dose dependency with the goal of establishing a safety profile required for a regulatory submission supporting the dosing of human subjects as outlined in appropriate ICH guidance. For the avoidance of doubt, preliminary toxicology studies are not regarded as a GLP Tox Study.", "hash": "4c5b4347244be665a824cd8983cafaa3", "id": 1}, {"size": 14, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "in-accordance-with", "type": "definition", "offset": [52, 70]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [75, 94]}, {"key": "duration-of", "type": "definition", "offset": [154, 165]}, {"key": "to-establish", "type": "clause", "offset": [206, 218]}, {"key": "investigational-new-drug-application", "type": "definition", "offset": [268, 304]}], "samples": [{"hash": "iMMsc6wdhOd", "uri": "/contracts/iMMsc6wdhOd#glp-tox-study", "label": "License and Transfer Agreement (Enumeral Biomedical Holdings, Inc.)", "score": 27.6119098663, "published": true}, {"hash": "1TRgTtaQKW4", "uri": "/contracts/1TRgTtaQKW4#glp-tox-study", "label": "License and Transfer Agreement (Pieris Pharmaceuticals, Inc.)", "score": 27.6091709137, "published": true}, {"hash": "85LuTMfIpff", "uri": "/contracts/85LuTMfIpff#glp-tox-study", "label": "License and Transfer Agreement (Pieris Pharmaceuticals, Inc.)", "score": 27.5489387512, "published": true}], "snippet": "means, with respect to a Product, a study conducted in accordance with GLP for the purposes of assessing the efficacy, safety or the onset, severity, and duration of toxic effects and their dose dependency to establish a profile sufficient to support the filing of an investigational new drug application.", "hash": "97421ebedfa2705e7a2908877a987572", "id": 2}, {"size": 4, "snippet_links": [{"key": "in-accordance-with", "type": "definition", "offset": [14, 32]}, {"key": "good-laboratory-practice", "type": "definition", "offset": [37, 61]}, {"key": "to-generate", "type": "definition", "offset": [68, 79]}, {"key": "hazards-and-risks", "type": "clause", "offset": [98, 115]}, {"key": "third-parties", "type": "definition", "offset": [140, 153]}, {"key": "the-environment", "type": "clause", "offset": [165, 180]}], "samples": [{"hash": "iybFpfyftFw", "uri": "/contracts/iybFpfyftFw#glp-tox-study", "label": "Research Collaboration and License Agreement (Pieris Pharmaceuticals, Inc.)", "score": 30.5920600891, "published": true}, {"hash": "8Mp6QVmuH78", "uri": "/contracts/8Mp6QVmuH78#glp-tox-study", "label": "Research Collaboration and License Agreement (Pieris Pharmaceuticals, Inc.)", "score": 27.5489387512, "published": true}, {"hash": "ju7a6rJpqKe", "uri": "/contracts/ju7a6rJpqKe#glp-tox-study", "label": "Research Collaboration and License Agreement (Pieris Pharmaceuticals, Inc.)", "score": 27.3244361877, "published": true}], "snippet": "means a study in accordance with the Good Laboratory Practice (GLP) to generate data by which the hazards and risks to users, consumers and third parties, including the environment, can be assessed for a product.", "hash": "9bc36e74548d219ac7dc97ce78411667", "id": 3}, {"size": 4, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [86, 105]}, {"key": "duration-of", "type": "definition", "offset": [165, 176]}], "samples": [{"hash": "kRhsH8TmPUb", "uri": "/contracts/kRhsH8TmPUb#glp-tox-study", "label": "License & Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.3148536682, "published": true}, {"hash": "evxEGHBtDHG", "uri": "/contracts/evxEGHBtDHG#glp-tox-study", "label": "License & Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 28.6084880829, "published": true}, {"hash": "hSKa1F23GyT", "uri": "https://ir.palvellatx.com/static-files/56d2d0f8-efe4-49a2-a2f4-2e7ad8b70264", "label": "Amendment", "score": 18.8748378754, "published": false}], "snippet": "means, with respect to a Product, a study conducted in a species using applicable GLP for the purposes of assessing the efficacy, safety or the onset, severity, and duration of toxic effects and their dose dependency with the goal of establishing a profile sufficient to support the filing of an IND.", "hash": "14689b39f726af8652e1e54580d03264", "id": 4}, {"size": 3, "snippet_links": [{"key": "toxicology-study", "type": "definition", "offset": [8, 24]}, {"key": "relationship-between", "type": "clause", "offset": [32, 52]}, {"key": "exposed-animal", "type": "definition", "offset": [81, 95]}, {"key": "the-study", "type": "definition", "offset": [107, 116]}, {"key": "in-accordance-with", "type": "definition", "offset": [136, 154]}, {"key": "establishment-of", "type": "clause", "offset": [249, 265]}, {"key": "the-product", "type": "definition", "offset": [290, 301]}, {"key": "clinical-studies", "type": "clause", "offset": [305, 321]}], "samples": [{"hash": "6RvUkLrUSPk", "uri": "/contracts/6RvUkLrUSPk#glp-tox-study", "label": "License Agreement (C4 Therapeutics, Inc.)", "score": 31.6913070679, "published": true}, {"hash": "aJiQGhI1qJ3", "uri": "/contracts/aJiQGhI1qJ3#glp-tox-study", "label": "License Agreement (C4 Therapeutics, Inc.)", "score": 31.5954818726, "published": true}], "snippet": "means a toxicology study of the relationship between dose and its effects on the exposed animal, where (a) the study is to be conducted in accordance with GLP standards and (b) the study has been designed in expectation that the results may support establishment of a safe starting dose of the Product in Clinical Studies.", "hash": "be4184406ebe7a955eb559701619fa1f", "id": 5}, {"size": 2, "snippet_links": [{"key": "toxicology-study", "type": "definition", "offset": [8, 24]}, {"key": "relationship-between", "type": "clause", "offset": [32, 52]}, {"key": "exposed-animal", "type": "definition", "offset": [80, 94]}, {"key": "anticipated-effects", "type": "clause", "offset": [103, 122]}, {"key": "the-study", "type": "definition", "offset": [213, 222]}, {"key": "in-accordance-with", "type": "definition", "offset": [242, 260]}, {"key": "good-laboratory-practices", "type": "definition", "offset": [261, 286]}, {"key": "establishment-of", "type": "clause", "offset": [368, 384]}, {"key": "clinical-studies", "type": "clause", "offset": [425, 441]}], "samples": [{"hash": "8RyEuUuP1Vo", "uri": "/contracts/8RyEuUuP1Vo#glp-tox-study", "label": "Collaboration and License Agreement (Monte Rosa Therapeutics, Inc.)", "score": 34.8535232544, "published": true}, {"hash": "4Zh2IvdOlTB", "uri": "https://ir.monterosatx.com/static-files/77c376a6-f847-4e8a-919a-dea2e3138952", "label": "ir.monterosatx.com", "score": 19.6769199371, "published": false}], "snippet": "means a toxicology study of the relationship between dose and its effects on an exposed animal (or its anticipated effects on humans where no animal is used in such a study, such as an organ-on-a-chip), where (i) the study is to be conducted in accordance with Good Laboratory Practices and (ii) the study has been designed in expectation that the results may support establishment of a safe starting dose of the Compound in Clinical Studies.", "hash": "38215eca568d38161bba436578280734", "id": 6}, {"size": 2, "snippet_links": [{"key": "a-non", "type": "clause", "offset": [6, 11]}, {"key": "clinical-study", "type": "definition", "offset": [12, 26]}, {"key": "in-accordance-with", "type": "definition", "offset": [37, 55]}, {"key": "adverse-effects", "type": "definition", "offset": [239, 254]}], "samples": [{"hash": "7yNXIL4Ouj4", "uri": "/contracts/7yNXIL4Ouj4#glp-tox-study", "label": "License Agreement (Global Blood Therapeutics, Inc.)", "score": 32.3401794434, "published": true}, {"hash": "le03yO5sPzQ", "uri": "https://ir.gbt.com/static-files/8efa38c4-d0de-432c-af84-4d9dd616f43e", "label": "ir.gbt.com", "score": 10.670088768, "published": false}], "snippet": "means a non-clinical study conducted in accordance with GLP to characterize the toxicity profile of a drug by identifying its physiological impact through non-human testing, which may include an assessment of dose and reversibility of any adverse effects.", "hash": "4da836c9051199abacb9a365b55c42aa", "id": 7}, {"size": 1, "snippet_links": [{"key": "toxicology-study", "type": "definition", "offset": [8, 24]}, {"key": "in-compliance-with", "type": "definition", "offset": [60, 78]}, {"key": "applicable-regulatory-requirements", "type": "definition", "offset": [139, 173]}, {"key": "data-and-results", "type": "clause", "offset": [264, 280]}, {"key": "applicable-regulatory-authority", "type": "clause", "offset": [363, 394]}, {"key": "certain-confidential-information", "type": "clause", "offset": [405, 437]}, {"key": "contained-in", "type": "definition", "offset": [438, 450]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [495, 567]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [568, 584]}, {"key": "securities-exchange-act-of-1934", "type": "clause", "offset": [598, 629]}, {"key": "as-amended", "type": "definition", "offset": [631, 641]}], "samples": [{"hash": "d9lqnBID8Nn", "uri": "/contracts/d9lqnBID8Nn#glp-tox-study", "label": "Collaboration and License Agreement (Sangamo Therapeutics, Inc)", "score": 29.3572902679, "published": true}], "snippet": "means a toxicology study of a product (a) that is conducted in compliance with GLP regulations in an animal species appropriate to satisfy applicable regulatory requirements, (b) that is otherwise designed to satisfy applicable regulatory requirements and (c) the data and results from which are intended to support the filing of an IND for such product with the applicable Regulatory Authority. 11 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.", "hash": "8e4a7dd4ae24d028145a7e825c7ae519", "id": 8}, {"size": 1, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "clinical-candidate", "type": "definition", "offset": [35, 53]}, {"key": "in-vivo", "type": "definition", "offset": [71, 78]}], "samples": [{"hash": "jpxJ9K6jp0I", "uri": "https://investor.stoketherapeutics.com/static-files/01e86a34-06bc-480d-a6c0-b91a5f41d03b", "label": "investor.stoketherapeutics.com", "score": 11.1765909195, "published": false}], "snippet": "means, with respect to a Molecule, Clinical Candidate or a Product, an in vivo", "hash": "540d83dcdef82cfe60fe7f17d632be34", "id": 9}, {"size": 1, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "licensed-compound", "type": "definition", "offset": [25, 42]}, {"key": "glp-toxicology-study", "type": "definition", "offset": [60, 80]}], "samples": [{"hash": "fQ0YWs5qXUk", "uri": "/contracts/fQ0YWs5qXUk#glp-tox-study", "label": "Collaboration and License Agreement (Generate Biomedicines, Inc.)", "score": 35.0930869268, "published": true}], "snippet": "means, with respect to a Licensed Compound, any preclinical GLP toxicology study of such Licensed Compound.", "hash": "b3ab546e6df0f9a660c7b0725547ff5e", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWZ2xwLXRveC1zdHVkeSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 50, "snippet": "means, with respect to a Compound, a study conducted in a species using applicable regulatory good laboratory practices for the purposes of assessing the onset, severity, and duration of toxic effects and their dose dependency with the goal of establishing a safety profile required for a regulatory submission supporting the dosing of human subjects as outlined in appropriate ICH guidance. For the avoidance of doubt, preliminary toxicology studies are not regarded as a GLP Tox Study.", "title": "GLP Tox Study", "id": "glp-tox-study", "examples": ["For the purposes of this Section 4.3.7, \u201cSignificant Study\u201d shall mean any <strong>GLP Tox Study</strong> or Clinical Study.", "Additional Backup Compounds may be progressed through a <strong>GLP Tox Study</strong> at Roche\u2019s sole discretion and expense (including any supply thereof) as part of the Research Plan and under the supervision of the JRC, provided that BPM will have the right to conduct (or have conducted) any such <strong>GLP Tox Study</strong>, and if BPM elects such right then Roche shall reimburse BPM for any personnel costs, Allocable Overhead or Out of Pocket Expenses incurred by BPM with respect thereto.", "A <strong>GLP Tox Study</strong> shall be started for a Product containing a Degronimid for which the JRD has determined that CCS Achieved has been reached.", "For the avoidance of doubt, preliminary toxicology studies are not regarded as a <strong>GLP Tox Study</strong>.", "The Parties shall form a Joint Development Committee (\u201cJDC\u201d) within [***] after the Initiation of the <strong>GLP Tox Study</strong> in the first species for a given Target to oversee all activities of a Phase I Plan of a Phase I Completed Original Product as well as clinical development of any C4T Co-Dev Products.", "Drafting of the Phase I Plan shall be initiated prior to completion of a <strong>GLP Tox Study</strong> for such Phase I Completed Original Product.", "For avoidance of doubt, any supply of Additional Dicerna Compounds by Dicerna to Roche prior to the Initiation of <strong>GLP Tox Study</strong> for use in or after the Initiation of <strong>GLP Tox Study</strong> (including manufacturing reservation and cancelation fees incurred under the Research Plan), shall be reimbursed to Dicerna by Roche.", "Notwithstanding anything to the contrary in the Platform Agreement, the Parties hereby agree that the initiation of the <strong>GLP Tox Study</strong>, as specified in Section 3.3 of the Platform Agreement, for the [***] Licensed Product will be deemed achieved on [***], such that SGEN will pay the milestone payment to PIRS for initiation of the <strong>GLP Tox Study</strong> for the [***] Licensed Product within [***] days after receiving the applicable invoice from PIRS on or after [***].", "Roche shall pay Dicerna\u2019s fully burdened manufacturing costs for supply of Additional Dicerna Compounds as requested by Roche for use in activities that will occur after Initiation of <strong>GLP Tox Study</strong>, and otherwise Roche shall have responsibility at its own expense for the supply of all Compounds, in each case for use in the R&amp;D Collaboration.", "If either (i) a First CD71 PDC is determined to have satisfied the CD71 GLP Tox Success Criteria, or (ii) AbbVie, in its sole and absolute discretion, elects by written notice to Licensor to continue Development of a CD71 PDC that does not satisfy the CD71 GLP Tox Success Criteria, then Licensor shall commence a <strong>GLP Tox Study</strong> in accordance with the CD71 Initial Development Plan and Budget for the particular First CD71 PDC candidate selected by AbbVie."], "related": [["phase-ii-clinical-study", "Phase II Clinical Study", "Phase II Clinical Study"], ["phase-i-study", "Phase I Study", "Phase I Study"], ["phase-i-clinical-study", "Phase I Clinical Study", "Phase I Clinical Study"], ["phase-iii-clinical-study", "Phase III Clinical Study", "Phase III Clinical Study"], ["phase-iii-study", "Phase III Study", "Phase III Study"]], "related_snippets": [], "updated": "2026-02-07T04:24:37+00:00"}, "json": true, "cursor": ""}}